Skip to main content

Table 2 Patient characteristics and distributions of IDH mutations for all patients and within groups

From: Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia

CHARACTERISTIC All IDH1 codon 132: IDH1 codon 105 (synonymous SNP): IDH2 codon 140: IDH2 codon 172:
Total n = 189   Wild type Mutation Wild type Variant Wild type Mutation Wild type Mutation
Age median (range), years 64 (19–88) 63 (19–85) 70 (30–88)* 64 (19–88) 66 (29–84) 63 (19–88) 66 (37–83)* 64 (19–88) 72 (46–74)*
Gender          
      Male 95 90 5 85 10 85 10 92 3
      Female 94 84 10 84 10 83 11 92 2
Karyotype          
      Normal 108 99 9 95 13 96 12 106 2
      Aberrant 75 69 6 68 7 66 9 72 3
      Missing data 6 6   6   6   6  
Risk group          
      Low 32 31 1 30 2 29 3 31 1
      Intermediate 87 80 7 72 15 75 12 86 1
      High 55 51 4 52 3 51 4 52 3
      Missing data 15 12 3 15   13 2 14 1
FLT3 status          
      FLT3 wild type 116 109 7 104 12 101 15 114 2
      FLT3-ITD 37 34 3 32 5 33 4 36 1
      Missing data** 36 31 5 33 3 34 2 34 2
      NPM1 status          
      NPM1 wild type 99 92 7 87 12 88 11 96 3
      NPM1 mutation 52 49 3 47 5 44 8 52 0
      Missing data** 38 33 5 35 3 36 2 36 2
Induction treatment response          
      Complete remission 132 122 10 119 13 119 13 127 5
      Not complete remission 49 44 5 43 6 43 6 49 0
      Missing information 8 8 0 7 1 6 2 8 0
IDH1 codon 132          
      Wild type 174    157 17 153 21 169 5
      Mutation 15    12 3 15 0 15 0
IDH1 codon 105 (synonymous SNP)          
      Wild type 169      151 18 165 5
      Variant 20      17 3 19 1
IDH2 codon 140          
      Wild type 168        163 5
      Mutation 21        21 0
IDH2 codon 172          
      Wild type 184         
      Mutation 5         
  1. *Mann–Whitney test for difference in age distribution between patients with IDH mutation (IDH1 or IDH2) and IDH wildtype patients, median 62 vs 69 years; p = 0.036.
  2. **FLT3-ITD and NPM1 mutations were not routinely analyzed in all non-normal karyotype patients.